Clinical Trial Update: A Phase I Multicentre Randomized Double-Blind Parallel-Controlled Study of HLX05-N vs. ERBITUX® in Metastatic Colorectal Cancer [Phase 1]

View source ↗

Summary

A Phase I multicentre randomized double-blind study comparing HLX05-N to Erbitux (cetuximab) in metastatic colorectal cancer; the trial is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• ERBITUX (cetuximab)
• HLX05-N

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: mCRC | Phase 1 | Status: NOT_YET_RECRUITING